X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Sacubitril/Valsartan is a modern ARNI agent and a cornerstone of heart failure therapy with reduced pump function. It often replaces an ACE inhibitor or a sartan there – provided it is started slowly and monitored carefully.
See more detail.gif)
Intake reminder, interaction check and your medication plan in one place. Free of charge.
Never stop or pause Sacubitril/Valsartan on your own. In heart failure, stopping abruptly can worsen the pump function – always agree on any changes with your practice. Sacubitril/Valsartan (brand name Entresto®) is a modern combination agent for treating chronic heart failure. It belongs to the ARNI class (angiotensin receptor–neprilysin inhibitors) and combines two points of attack in a single tablet: the neprilysin inhibitor sacubitril and the sartan valsartan.
| Property | Details |
|---|---|
| Active ingredient | Sacubitril/Valsartan |
| Brand name | Entresto® |
| ATC code | C09DX04 |
| Drug class | ARNI – neprilysin inhibitor + angiotensin receptor blocker |
| Formulation | Film-coated tablets 24/26 mg, 49/51 mg, 97/103 mg |
| Intake | Twice daily, independent of meals |
| Standard dose | Target dose 97/103 mg twice/day (titrated up) |
| Indication | Chronic heart failure with reduced pump function (HFrEF) |
| Prescription only | Yes |
Sacubitril/Valsartan acts at two sites at once in heart failure – hence the name ARNI. This explains why the combination can do more than a single sartan.
The sacubitril component inhibits the enzyme neprilysin. Neprilysin normally breaks down the body's own vessel-protecting messengers – the so-called natriuretic peptides. When neprilysin is slowed down, these peptides stay active longer: the vessels widen, the body excretes more salt and water, and the heart is relieved. The valsartan component blocks – like the pure sartan valsartan – the angiotensin receptor and thereby lowers blood pressure and the strain on the heart.
Together, both building blocks help the weakened heart pump more effectively. In large studies, Sacubitril/Valsartan reduced hospital admissions and mortality more than an ACE inhibitor alone in heart failure with reduced pump function. That is why the agent is a mainstay of modern heart failure therapy today and often replaces an ACE inhibitor or a sartan there.
Sacubitril/Valsartan is taken twice daily, in the morning and in the evening, independent of food. Treatment starts at a low dose and is increased step by step – usually every two to four weeks – up to the target dose. This lets the circulation get used to the blood-pressure-lowering effect.
| Situation | Dose |
|---|---|
| Starting dose (standard) | 49/51 mg twice/day |
| Low start (low blood pressure, prior medication) | 24/26 mg twice/day |
| Target dose | 97/103 mg twice/day |
| Impaired kidney or liver function | Lower start, slower titration |
A missed dose is taken as soon as you notice it – but if the next dose is already near, the missed one is skipped. Never take a double amount at once. What generally applies to a missed dose is explained in the guide Forgotten medication.
brite reliably reminds you of your morning and evening intake and documents it seamlessly.
In heart failure with reduced pump function, Sacubitril/Valsartan competes with the classic inhibitors of the renin–angiotensin system: the ACE inhibitors such as ramipril and the sartans such as valsartan. The ARNI is preferred in suitable patients and then replaces one of these medicines – it is not given in addition to them.
| Property | ARNI (Sacubitril/Valsartan) | ACE inhibitor | Sartan |
|---|---|---|---|
| Point of attack | Neprilysin + angiotensin receptor | ACE enzyme | Angiotensin receptor |
| Intake | Twice daily | Once to twice daily | Once daily |
| Role in HFrEF | Preferred, replaces ACE inhibitor/sartan | Established basis | Alternative for dry cough |
| Dry cough | Rare | More common | Rare |
| Special note | 36 h gap after ACE inhibitor required | Do not combine with ARNI | Not in addition to the ARNI |
Whether an ARNI, an ACE inhibitor or a sartan is the right choice depends on the pump function, the blood pressure, the kidney function and how well it is tolerated. Alongside these agents, the basic therapy for heart failure usually also includes a beta blocker such as bisoprolol and an aldosterone antagonist such as spironolactone. The doctor makes the choice individually.
The most common side effect follows directly from the effect: blood pressure that is too low. It shows up as dizziness, especially when standing up. Kidney values and the potassium level can also change.
| Side effect | Frequency | What to do? |
|---|---|---|
| Low blood pressure, dizziness | Common | Stand up slowly; inform your practice if dizziness is severe |
| Raised potassium in the blood | Common | Monitoring as instructed; avoid potassium-rich supplements |
| Worsened kidney values | Uncommon | Regular blood checks |
| Angioedema (swelling of the face, lips, tongue, throat) | Rare | Emergency – call 112 immediately |
Sacubitril/Valsartan affects blood pressure, potassium and the kidney balance – so some combinations are critical. Check them in the interaction check.
| Substance / medicine | Interaction | Recommendation |
|---|---|---|
| ACE inhibitors (ramipril, enalapril) | Sharply increased angioedema risk | Strictly contraindicated; 36 h gap |
| Other sartans (e.g. valsartan) | Double blockade, no added benefit | Do not combine |
| Potassium-sparing agents (spironolactone), potassium supplements | Potassium can rise dangerously | Only with monitoring of the potassium level |
| NSAIDs (ibuprofen, diclofenac) | Weaken the effect, strain the kidney | Avoid, especially with kidney weakness |
Because Sacubitril/Valsartan affects blood pressure, potassium and kidney function, regular blood and blood-pressure checks are part of the therapy – above all during the adjustment phase and after each dose increase. Potassium and the kidney values are checked; if needed, the practice adjusts the dose. A well-controlled chronic kidney disease does not rule out the therapy, but requires closer monitoring.
When switching from an ACE inhibitor to the ARNI, the 36-hour break is mandatory. Switching from a sartan is more straightforward, because there is no additional angioedema risk. During pregnancy, Sacubitril/Valsartan must not be taken. Never stop the medicine on your own – a digital medication plan helps you keep track of all your heart medicines.
With brite you have your medication plan ready for every visit to the doctor and clinic.
